A detailed history of Deutsche Bank Ag\ transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 19,519 shares of IPSC stock, worth $23,617. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,519
Previous 7,261 168.82%
Holding current value
$23,617
Previous $18,000 83.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.44 - $3.29 $17,651 - $40,328
12,258 Added 168.82%
19,519 $33,000
Q2 2024

Aug 14, 2024

SELL
$2.46 - $4.05 $6,083 - $10,015
-2,473 Reduced 25.41%
7,261 $18,000
Q1 2024

May 15, 2024

SELL
$3.19 - $5.32 $59,834 - $99,787
-18,757 Reduced 65.83%
9,734 $40,000
Q4 2023

Feb 14, 2024

BUY
$1.28 - $3.32 $35,048 - $90,908
27,382 Added 2469.07%
28,491 $94,000
Q3 2023

Nov 09, 2023

SELL
$2.0 - $3.23 $44,940 - $72,578
-22,470 Reduced 95.3%
1,109 $2,000
Q2 2023

Aug 14, 2023

BUY
$2.91 - $3.53 $32,356 - $39,250
11,119 Added 89.24%
23,579 $74,000
Q1 2023

May 15, 2023

BUY
$3.4 - $5.11 $17,387 - $26,132
5,114 Added 69.62%
12,460 $43,000
Q4 2022

Feb 13, 2023

BUY
$4.84 - $11.58 $658 - $1,574
136 Added 1.89%
7,346 $37,000
Q3 2022

Nov 14, 2022

SELL
$8.57 - $13.1 $11,526 - $17,619
-1,345 Reduced 15.72%
7,210 $71,000
Q2 2022

Aug 11, 2022

SELL
$7.96 - $12.43 $14,312 - $22,349
-1,798 Reduced 17.37%
8,555 $72,000
Q1 2022

May 13, 2022

BUY
$11.62 - $15.92 $36,928 - $50,593
3,178 Added 44.29%
10,353 $131,000
Q4 2021

Feb 11, 2022

BUY
$13.93 - $23.62 $5,293 - $8,975
380 Added 5.59%
7,175 $114,000
Q3 2021

Nov 04, 2021

BUY
$20.8 - $31.93 $141,336 - $216,964
6,795 New
6,795 $171,000

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $71.2M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.